UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

JANUARY 10, 2018
Date of Report (Date of earliest event reported)

 

GALA PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

 

NEVADA 000-52044 42-1771014
(State or other jurisdiction of (Commission File (IRS Employer Identification No.)
incorporation) Number)  

 

     
2780 South Jones Blvd., #3725, Las Vegas, Nevada 89146
(Address of principal executive offices) (Zip Code)

 

(949) 851-9261
Registrant's telephone number, including area code

 

                            GALA GLOBAL INC.                            

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

     

 

 

 

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

 

As of January 19, 2018, the relationship with Joseph Earle, the recently appointed Chief Operation Officer, was ended along with the related consulting agreement. As litigation is possible from this event, any documents or communication sent to or received from Mr. Earle or his attorney are being handled directly by our attorney.

 

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

 

Gala Global Inc., effective January 10, 2018 has changed its name to Gala Pharmaceutical, Inc. On or about December 4, 2017, a majority of Gala Global, Inc. shareholders consented to the change which was approved by the Board of Directors the same day. On December 5, 2018 the Articles of Incorporation were amended to reflect the name change.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits

 

Exhibit No. Description
   
3.1 Certificate of Amendment to Certificate of Incorporation

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Gala Pharmaceutical Inc.
     
Date: February 1, 2018 By: /s/ Maqsood Rehman
    Maqsood Rehman
  Title: Chief Executive Officer

 

 

Exhibit 3.1

 

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

 

 

 

   
Certificate of Amendment  
(PURSUANT TO NRS 78.385 and 78.390)  
   
   

 

 

Article I has been changed. The new name of the corporation is:

 

Gala Pharmaceutical, Inc.

 

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

 

1. Name of Corporation: Gala Pharmaceutical, Inc.

  

2. The articles have been amended as follows: (provide article numbers, if available)

 

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is:         

 

4. Effective date and time of filing:      Date:                          Time:

 

5. Signature:

 

/s/ Maqsood Rehman  

 

* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.